BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rilvegostomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rilvegostomig\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04379596-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study 
 of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressi
 ng Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0437
 9596
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686305-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rilvegostomig: Phase 1 readout est. (NCT04686305)
DESCRIPTION:Rilvegostomig\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Wit
 hout Chemotherapy in Advanced or Metastatic HER2+\, Non-squamous NSCLC\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04686305
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161414-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270719
DTEND;VALUE=DATE:20270720
SUMMARY:Rilvegostomig: Phase 1 readout est. (NCT07161414)
DESCRIPTION:Rilvegostomig\, phase 1.\nStudy: A Study to Investigate the Pha
 rmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participan
 ts With Advanced Solid Tumors Previously Treated With Standard of Care The
 rapy\nEstimated primary completion: 19 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07161414
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05414032-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05414032)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: Molecular Residual Disease Int
 erception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05414032
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Participants 
 With Advanced/Metastatic Solid Malignancies\nEstimated primary completion:
  29 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05123482
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Rilvegostomig\, phase 2\, Biliary Tract Cancer.\nStudy: Study o
 f Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Pa
 tients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary
  completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069712-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07069712)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: A Study of Novel Agents or Com
 binations as Perioperative Treatment in Participants With Locally Advanced
  Resectable Gastroesophageal Adenocarcinoma\nEstimated primary completion:
  9 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ril
 vegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07069712
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Novel Combina
 tions in Participants With Locally Advanced Unresectable or Metastatic Gas
 tric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05702229
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03741426-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT03741426)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: WIRE - Novel Treatments in Ren
 al Cell Cancer\nEstimated primary completion: 30 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03741426
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06569225-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT06569225)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: Gemcitabine/Cisplatin/Nab-Pacl
 itaxel and Rilvegostomig in Resectable iCCA\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 lvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06569225
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04995523-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT04995523)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participan
 ts With Advanced or Metastatic NSCLC\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0499
 5523
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467357-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06467357)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: Phase 3
  Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing B
 iliary Tract Cancer\nEstimated primary completion: 12 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06467357
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Perioperative
  Therapies in Locally Advanced Unresectable Gastric Cancer\nEstimated prim
 ary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109779-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06109779)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: Rilvego
 stomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After R
 esection (ARTEMIDE-Biliary01)\nEstimated primary completion: 2 January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109779
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Rilvegostomig\, phase 3\, Endometrial Cancer.\nStudy: DESTINY-E
 ndometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostom
 ig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)
 \, Mismatch Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary
  completion: 19 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 23 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06005493-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290316
DTEND;VALUE=DATE:20290317
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT06005493)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Gastric Cancer.\nStudy: Study of AZ
 D5863 in Adult Participants With Advanced or Metastatic Solid Tumors\nEsti
 mated primary completion: 16 March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06005493
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Rilvegostomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nEstima
 ted primary completion: 6 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Rilvegostomig\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ S
 tudy of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab
  Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer\n
 Estimated primary completion: 27 April 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128290-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07128290)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: PErioperative CISGEM + Rilvego
 stomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma\nEstimated
  primary completion: 30 April 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07128290
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221253-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07221253)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: A Study
  of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment
  of Biliary Tract Cancer (ARTEMIDE-Biliary02)\nEstimated primary completio
 n: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilv
 egostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07221253
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Rilvegostomig\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug V
 edotin in Combination With Capecitabine With or Without Rilvegostomig in P
 articipants With Advanced or Metastatic Gastric\, Gastroesophageal Junctio
 n\, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary
  completion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115043-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT07115043)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety of AZD6750 in Adult Participants With Selec
 t Advanced or Metastatic Solid Tumors\nEstimated primary completion: 2 Oct
 ober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegosto
 mig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07115043
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357533-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06357533)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase III\, Open-label\, Study of First-line Dato-DXd in Combination With R
 ilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (T
 C ≥ 50%) and Without Actionable Genomic Alterations\nEstimated primary c
 ompletion: 28 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06357533
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868277-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20300117
DTEND;VALUE=DATE:20300118
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06868277)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for 
 First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer\n
 Estimated primary completion: 17 January 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06868277
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Rilvegostomig\, phase 3\, Hepatocellular Carcinoma.\nStudy: Pha
 se III Study of Rilvegostomig in Combination With Bevacizumab With or With
 out Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEsti
 mated primary completion: 15 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Rilvegostomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
 \nEstimated primary completion: 28 May 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788664-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07788664)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Local and Sys
 temic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Adv
 anced Gastric Cancer (RILVE Project)\nEstimated primary completion: 1 June
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0778
 8664
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692738-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06692738)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherap
 y for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-
 small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1 July 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06692738
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720284-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20300911
DTEND;VALUE=DATE:20300912
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07720284)
DESCRIPTION:Rilvegostomig\, phase 3\, Urothelial Carcinoma.\nStudy: An Open
 -label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegos
 tomig vs SoC in Adult Participants With High-risk MIUC\nEstimated primary 
 completion: 11 September 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07720284
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627647-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20301118
DTEND;VALUE=DATE:20301119
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06627647)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherap
 y for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous 
 NSCLC\nEstimated primary completion: 18 November 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06627647
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and P
 ersonalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primar
 y completion: December 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04541108-1986@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Rilvegostomig: Phase 1 readout est. (NCT04541108)
DESCRIPTION:Rilvegostomig\, phase 1.\nStudy: Phase 0 Master Protocol for CI
 VO Intratumoral Microdosing of Anti-Cancer Therapies\nEstimated primary co
 mpletion: December 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04541108
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
